Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges
Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug resistance and other contributing factors, the scientific community needs to look for new alternatives, and drug repurposing is one of the best op...
Saved in:
| Published in | Biomedicine & pharmacotherapy Vol. 145; p. 112375 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
France
Elsevier Masson SAS
01.01.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug resistance and other contributing factors, the scientific community needs to look for new alternatives, and drug repurposing is one of the best opportunities. Here we light upon the drug repurposing with a major focus on breast cancer. BC is a division of cancer known as the leading cause of death of 2.3 million women globally, with 685,000 fatalities. This number is steadily rising, necessitating the development of a treatment that can extend survival time. All available treatments for BC are very costly as well as show side effects. This unfulfilled requirement of the anti-cancer drugs ignited an enthusiasm for drug repositioning, which means finding out the anti-cancer use of already marketed drugs for other complications. With the advancement in proteomics, genomics, and computational approaches, the drug repurposing process hastens. So many drugs are repurposed for the BC, including alkylating agents, antimetabolite, anthracyclines, an aromatase inhibitor, mTOR, and many more. The drug resistance in breast cancer is rising, so reviewing how the challenges in breast cancer can be combated with drug repurposing. This paper provides the updated information on all the repurposed drugs candidates for breast cancer with the molecular mechanism responsible for their anti-tumor activity. Additionally, all the challenges that occur during the repurposing of the drugs are discussed.
[Display omitted]
•BC is a division of cancer known as the leading cause of death in women globally, and second, in the US, roughly 50% of the women without known risk factors suffered from BCs.•The primary cause of death due to BC is the resistance to conventional chemotherapeutic agents responsible for recurrence and relapse of cancer, despite various advancements in breast cancer therapy.•The drug purposing against BC explores the therapeutic use of existing clinically approved, off-patent drugs with known targets for another indication to minimize the cost of therapy, time, and risk.•Drug repurposed against BC with existing knowledge of molecular targets can be an excellent approach towards treatment. |
|---|---|
| AbstractList | Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug resistance and other contributing factors, the scientific community needs to look for new alternatives, and drug repurposing is one of the best opportunities. Here we light upon the drug repurposing with a major focus on breast cancer. BC is a division of cancer known as the leading cause of death of 2.3 million women globally, with 685,000 fatalities. This number is steadily rising, necessitating the development of a treatment that can extend survival time. All available treatments for BC are very costly as well as show side effects. This unfulfilled requirement of the anti-cancer drugs ignited an enthusiasm for drug repositioning, which means finding out the anti-cancer use of already marketed drugs for other complications. With the advancement in proteomics, genomics, and computational approaches, the drug repurposing process hastens. So many drugs are repurposed for the BC, including alkylating agents, antimetabolite, anthracyclines, an aromatase inhibitor, mTOR, and many more. The drug resistance in breast cancer is rising, so reviewing how the challenges in breast cancer can be combated with drug repurposing. This paper provides the updated information on all the repurposed drugs candidates for breast cancer with the molecular mechanism responsible for their anti-tumor activity. Additionally, all the challenges that occur during the repurposing of the drugs are discussed.Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug resistance and other contributing factors, the scientific community needs to look for new alternatives, and drug repurposing is one of the best opportunities. Here we light upon the drug repurposing with a major focus on breast cancer. BC is a division of cancer known as the leading cause of death of 2.3 million women globally, with 685,000 fatalities. This number is steadily rising, necessitating the development of a treatment that can extend survival time. All available treatments for BC are very costly as well as show side effects. This unfulfilled requirement of the anti-cancer drugs ignited an enthusiasm for drug repositioning, which means finding out the anti-cancer use of already marketed drugs for other complications. With the advancement in proteomics, genomics, and computational approaches, the drug repurposing process hastens. So many drugs are repurposed for the BC, including alkylating agents, antimetabolite, anthracyclines, an aromatase inhibitor, mTOR, and many more. The drug resistance in breast cancer is rising, so reviewing how the challenges in breast cancer can be combated with drug repurposing. This paper provides the updated information on all the repurposed drugs candidates for breast cancer with the molecular mechanism responsible for their anti-tumor activity. Additionally, all the challenges that occur during the repurposing of the drugs are discussed. Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug resistance and other contributing factors, the scientific community needs to look for new alternatives, and drug repurposing is one of the best opportunities. Here we light upon the drug repurposing with a major focus on breast cancer. BC is a division of cancer known as the leading cause of death of 2.3 million women globally, with 685,000 fatalities. This number is steadily rising, necessitating the development of a treatment that can extend survival time. All available treatments for BC are very costly as well as show side effects. This unfulfilled requirement of the anti-cancer drugs ignited an enthusiasm for drug repositioning, which means finding out the anti-cancer use of already marketed drugs for other complications. With the advancement in proteomics, genomics, and computational approaches, the drug repurposing process hastens. So many drugs are repurposed for the BC, including alkylating agents, antimetabolite, anthracyclines, an aromatase inhibitor, mTOR, and many more. The drug resistance in breast cancer is rising, so reviewing how the challenges in breast cancer can be combated with drug repurposing. This paper provides the updated information on all the repurposed drugs candidates for breast cancer with the molecular mechanism responsible for their anti-tumor activity. Additionally, all the challenges that occur during the repurposing of the drugs are discussed. [Display omitted] •BC is a division of cancer known as the leading cause of death in women globally, and second, in the US, roughly 50% of the women without known risk factors suffered from BCs.•The primary cause of death due to BC is the resistance to conventional chemotherapeutic agents responsible for recurrence and relapse of cancer, despite various advancements in breast cancer therapy.•The drug purposing against BC explores the therapeutic use of existing clinically approved, off-patent drugs with known targets for another indication to minimize the cost of therapy, time, and risk.•Drug repurposed against BC with existing knowledge of molecular targets can be an excellent approach towards treatment. Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug resistance and other contributing factors, the scientific community needs to look for new alternatives, and drug repurposing is one of the best opportunities. Here we light upon the drug repurposing with a major focus on breast cancer. BC is a division of cancer known as the leading cause of death of 2.3 million women globally, with 685,000 fatalities. This number is steadily rising, necessitating the development of a treatment that can extend survival time. All available treatments for BC are very costly as well as show side effects. This unfulfilled requirement of the anti-cancer drugs ignited an enthusiasm for drug repositioning, which means finding out the anti-cancer use of already marketed drugs for other complications. With the advancement in proteomics, genomics, and computational approaches, the drug repurposing process hastens. So many drugs are repurposed for the BC, including alkylating agents, antimetabolite, anthracyclines, an aromatase inhibitor, mTOR, and many more. The drug resistance in breast cancer is rising, so reviewing how the challenges in breast cancer can be combated with drug repurposing. This paper provides the updated information on all the repurposed drugs candidates for breast cancer with the molecular mechanism responsible for their anti-tumor activity. Additionally, all the challenges that occur during the repurposing of the drugs are discussed. |
| ArticleNumber | 112375 |
| Author | Ahmed, Sakeel Al Hagbani, Turki Malik, Jonaid Ahmad Bender, Onur Alqarni, Aali Anwar, Sirajudheen Jan, Bisma |
| Author_xml | – sequence: 1 givenname: Jonaid Ahmad surname: Malik fullname: Malik, Jonaid Ahmad organization: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati, India – sequence: 2 givenname: Sakeel surname: Ahmed fullname: Ahmed, Sakeel organization: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Mohali, India – sequence: 3 givenname: Bisma surname: Jan fullname: Jan, Bisma organization: Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, India – sequence: 4 givenname: Onur surname: Bender fullname: Bender, Onur organization: Biotechnology Institute, Ankara University, Ankara, Turkey – sequence: 5 givenname: Turki surname: Al Hagbani fullname: Al Hagbani, Turki organization: Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Saudi Arabia – sequence: 6 givenname: Aali surname: Alqarni fullname: Alqarni, Aali organization: Pharmaceutical Chemistry Department, Pharmacology unit, College of Clinical Pharmacy, Al Baha University, Saudi Arabia – sequence: 7 givenname: Sirajudheen surname: Anwar fullname: Anwar, Sirajudheen email: si.anwar@uoh.edu.sa organization: Pharmacology and Toxicology Department, College of Pharmacy, University of Hail, Hail, Saudi Arabia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34863612$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcFq3DAQhkVISTZp36AUHXvxdmTZ8m4OhZCkTSHQS3sW49E4q8VruZKckrevFyeXHtrTMPB9P8P8F-J0CAML8V7BWoEyn_br1odxh-sSSrVWqtRNfSJWaltDYQCaU7GCptaF1mV5Li5S2gNAbfTmTJzramO0UeVK0G2cHpOMPE5xDIndlbweJLonHIidTJlHmcNvjC7JvGOZI2M-8JBl6GQ7LylLOrJR4uAkphTIY55V2mHf8_DI6a1402Gf-N3LvBQ_v9z9uLkvHr5__XZz_VBQ1VS5qEvAzoFuoXNM2iG3nVGum6_mCsi1AOxQM263tamJFJvGEJUbrYhaVPpSfFxyxxh-TZyyPfhE3Pc4cJiSLQ00GrSqqxn98IJO7YGdHaM_YHy2r4-ZgasFoBhSitxZ8hmzD0OO6HurwB5bsHu7tGCPLdilhVmu_pJf8_-jfV40np_05DnaRJ6PPfjIlK0L_t8BfwC_GKSa |
| CitedBy_id | crossref_primary_10_1016_j_csbj_2023_06_003 crossref_primary_10_1080_07391102_2024_2437548 crossref_primary_10_2147_DDDT_S417563 crossref_primary_10_1016_j_lfs_2022_120789 crossref_primary_10_51753_flsrt_1152416 crossref_primary_10_12677_MD_2023_133052 crossref_primary_10_1515_ntrev_2022_0154 crossref_primary_10_1002_ddr_22184 crossref_primary_10_1016_j_compbiolchem_2024_108255 crossref_primary_10_4155_tde_2023_0020 crossref_primary_10_1088_1361_6528_ad6fa6 crossref_primary_10_1016_j_heliyon_2024_e31131 crossref_primary_10_3390_biology12030467 crossref_primary_10_1016_j_medidd_2024_100177 crossref_primary_10_1038_s41540_024_00359_z crossref_primary_10_1021_acsomega_2c07793 crossref_primary_10_3389_fphar_2023_1143102 crossref_primary_10_1111_cbdd_14452 crossref_primary_10_1186_s12885_022_10200_7 crossref_primary_10_1515_oncologie_2022_1011 crossref_primary_10_3390_ijms252212441 crossref_primary_10_1016_j_rechem_2024_101694 crossref_primary_10_1002_ardp_202200407 crossref_primary_10_1016_j_ijpx_2024_100249 crossref_primary_10_3390_pharmaceutics14061196 crossref_primary_10_3390_plants13010035 crossref_primary_10_3390_molecules27227668 crossref_primary_10_1016_j_sajb_2023_12_043 crossref_primary_10_1002_slct_202403773 crossref_primary_10_3390_molecules28135253 crossref_primary_10_1016_j_ijpharm_2025_125385 crossref_primary_10_1021_acsmedchemlett_2c00182 crossref_primary_10_2147_JMDH_S449465 crossref_primary_10_47836_mjmhs_19_6_29 crossref_primary_10_1016_j_bspc_2025_107686 crossref_primary_10_1021_acsomega_2c05821 crossref_primary_10_3897_pharmacia_71_e117997 crossref_primary_10_1007_s44337_024_00012_y crossref_primary_10_1007_s00210_025_03853_1 crossref_primary_10_1007_s11033_023_09131_8 crossref_primary_10_3390_app12115554 crossref_primary_10_1007_s12032_022_01863_0 crossref_primary_10_1186_s12645_025_00313_6 crossref_primary_10_3390_ijms23084280 crossref_primary_10_1038_s41598_024_73083_7 crossref_primary_10_3390_nu15132884 crossref_primary_10_1016_j_lfs_2023_121389 crossref_primary_10_1186_s12967_024_05429_8 crossref_primary_10_1016_j_jconrel_2024_10_013 crossref_primary_10_4062_biomolther_2024_131 crossref_primary_10_1007_s12063_024_00533_w crossref_primary_10_1016_j_ijpharm_2024_123800 crossref_primary_10_1007_s42452_023_05356_1 crossref_primary_10_1007_s00210_024_03151_2 crossref_primary_10_1002_cyto_a_24768 crossref_primary_10_1016_j_patter_2022_100470 crossref_primary_10_1016_j_jddst_2024_106007 |
| Cites_doi | 10.1038/s41416-020-0857-z 10.3390/ijms21030755 10.1001/jamanetworkopen.2021.14904 10.1358/dnp.2010.23.8.1500435 10.1038/nrd1031 10.1155/2015/341362 10.2147/IJN.S127329 10.1186/s12885-016-2999-1 10.1159/000227243 10.1200/JCO.2016.68.4480 10.1038/sj.onc.1206943 10.1016/S1474-4422(14)70222-4 10.2147/CMAR.S178567 10.1007/s10549-011-1612-1 10.1038/s41598-019-41632-0 10.2147/CMAR.S200059 10.1007/978-3-319-43896-2_1 10.2147/IJN.S257700 10.7150/jca.47470 10.1177/2050312119865114 10.1007/s13304-017-0424-1 10.1007/s11095-008-9770-5 10.1001/jama.2018.19323 10.3892/ijo.2015.3298 10.1038/nrc1590 10.1038/onc.2017.328 10.1172/JCI30558 10.1038/nrd.2018.168 10.3390/molecules24203659 10.1158/1940-6207.CAPR-13-0181 10.1186/1750-2187-3-18 10.1158/0008-5472.CAN-15-1233 10.1056/NEJMoa0707056 10.1038/d41573-021-00002-0 10.1016/j.colsurfb.2012.02.039 10.3892/ol.2021.12876 10.1016/j.semcancer.2019.09.012 10.3389/fimmu.2021.635371 10.1016/j.ejps.2020.105401 10.1016/j.tips.2016.03.004 10.1007/s10549-019-05381-y 10.2147/DDDT.S141675 10.1093/jnci/djq457 10.3389/fphar.2019.01664 10.1371/journal.pone.0224309 10.1038/sj.bjc.6603158 10.1111/j.1476-5381.1993.tb13840.x 10.1016/S0006-2952(98)00307-4 10.3390/pharmaceutics13081189 10.1016/j.jconrel.2014.12.030 10.1016/j.jss.2017.05.101 10.1007/978-0-387-74039-3_1 10.1016/j.prostaglandins.2019.106379 10.1371/journal.pone.0252822 10.7150/ijbs.9224 10.3390/jpm10040200 10.1186/bcr1864 10.1038/534314a 10.1016/j.hemonc.2019.08.008 10.1158/1535-7163.MCT-16-0451 10.1016/S0014-4827(03)00223-4 10.1016/j.biopha.2021.111285 10.1001/jama.282.20.1921 10.1007/s00432-010-0854-3 10.1016/j.canlet.2011.06.032 10.1200/JCO.2011.39.7505 10.1177/1758834017711097 10.1016/S0002-9610(00)00507-9 10.1186/s13058-020-01348-w 10.1093/neuonc/nou139 10.1023/A:1006348907994 10.1038/nature12626 10.3389/fphar.2020.592912 10.1007/s10620-014-3040-7 10.1186/2052-8426-2-15 10.1634/theoncologist.2015-0096 10.1016/j.clbc.2013.10.014 10.7573/dic.212579 10.1038/s41586-019-1005-x 10.1186/s12967-016-1031-5 10.1016/j.bcp.2019.04.026 10.1007/s10911-019-09429-z 10.1016/j.heliyon.2021.e05948 10.1002/cam4.1687 10.1586/14737140.1.3.334 10.1093/jnci/dji372 10.1007/s00432-010-0893-9 10.1038/s41389-017-0025-3 10.1023/A:1026476801463 10.2165/00003495-200565170-00007 10.1128/AAC.01101-20 10.1016/j.tca.2005.09.011 10.1007/978-3-662-11496-4_24 10.1073/pnas.83.12.4514 10.1007/978-3-030-20301-6_22 10.7150/jca.29739 10.1007/s00280-015-2947-9 10.1056/NEJMoa1103507 10.1016/j.bbrc.2005.05.174 10.1038/nrc1074 10.4161/cbt.3.2.692 10.1053/jhep.2003.50380 10.1093/annonc/mdv221 10.1097/01.LAB.0000073128.16098.31 10.1185/030079903125002397 10.1200/JCO.20.02598 10.1016/j.semcancer.2020.02.003 10.1186/s12929-018-0478-5 10.1023/A:1006338232150 10.5732/cjc.011.10329 10.1200/JCO.2008.20.5013 10.1007/s10072-015-2259-1 10.3390/cancers10030080 10.1677/erc.1.01004 10.1146/annurev.genom.9.081307.164339 10.1016/j.tips.2013.06.005 10.1002/jcb.22239 10.1038/srep21164 10.2174/1381612043453117 10.1007/978-1-4419-0802-5_18 10.3332/ecancer.2014.485 10.18632/oncotarget.3699 10.1038/nature07483 10.1038/clpt.2013.1 10.1038/s41467-017-00680-8 10.1002/bies.20238 10.1186/1478-811X-8-23 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| Copyright_xml | – notice: 2021 The Authors – notice: Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.biopha.2021.112375 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1950-6007 |
| ExternalDocumentID | 34863612 10_1016_j_biopha_2021_112375 S0753332221011598 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 0SF 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 6I. 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAFTH AAFWJ AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO ABBQC ABFNM ABLVK ABMAC ABMZM ABXDB ABYKQ ABZDS ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFPKN AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AI. AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA GROUPED_DOAJ HMT HVGLF HZ~ IHE J1W KOM LCYCR M34 M41 MO0 N9A NCXOZ O-L O9- OAUVE OD~ OGGZJ OK1 OO0 OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SEM SES SEW SPT SSH SSP SSZ T5K VH1 WUQ Z5R ~02 ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO ADVLN AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
| ID | FETCH-LOGICAL-c474t-520afd03b0fdec3daebf61df005e40cdb00eda3ea99565cc1e676cc2831ccba13 |
| IEDL.DBID | .~1 |
| ISSN | 0753-3322 1950-6007 |
| IngestDate | Tue Aug 05 10:33:08 EDT 2025 Wed Feb 19 02:27:24 EST 2025 Thu Apr 24 23:10:15 EDT 2025 Tue Jul 01 04:13:00 EDT 2025 Fri Feb 23 02:37:45 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | DHEA PR CDK p53 H-ras OCT1 EREs CSCs AA SERD CTs AE SERM NCC NCE AT SMAD 2/3/4 BRAC1 TP53 MHS2 ABCG2 ERK MRC BC ABC NSAID RTK Drug repurposing IBD HPT SC SIRT1/2 CC SS EHRs 8-Oxo-dG S6K Breast cancer ECM TC HER1/2 SQLE CCGs TAE TOP2A TAM 3β-HSD DI ALS DBF DM MDA 17β-HSD Drug resistance MetAP2 DR LHRH NF-κB Sp1/3/4 GSKβ TRP DBS SLC22A16 MC MD mTOR MDR Rac1 P-gp MT TSE IGF-1 MAPK PEG2/PGH2 EMT ER LSS MTs MMP RCTs ROS MVD COX-2 ROCK1 Molecular mechanism HMGCS SCTs HMGCR NPO DHEAS Repurposing challenges TGFβ-RI XDH β-act NQO1 DTs NOS3 VEGF EP1 STAT3 TGFβ1/β2 GST MLH1 FAK HER ERCC2 Rho-A TGFα HD HER2 HNE |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-520afd03b0fdec3daebf61df005e40cdb00eda3ea99565cc1e676cc2831ccba13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0753332221011598 |
| PMID | 34863612 |
| PQID | 2607303154 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2607303154 pubmed_primary_34863612 crossref_citationtrail_10_1016_j_biopha_2021_112375 crossref_primary_10_1016_j_biopha_2021_112375 elsevier_sciencedirect_doi_10_1016_j_biopha_2021_112375 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2022 2022-01-00 2022-Jan 20220101 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: January 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Biomedicine & pharmacotherapy |
| PublicationTitleAlternate | Biomed Pharmacother |
| PublicationYear | 2022 |
| Publisher | Elsevier Masson SAS |
| Publisher_xml | – name: Elsevier Masson SAS |
| References | Ponce-Cusi, Calaf (bib71) 2016; 48 Bezprozvanny (bib150) 2010; 23 Sparano, Makhson, Semiglazov, Tjulandin, Balashova, Bondarenko, Bogdanova, Manikhas, Oliynychenko, Chatikhine, Zhuang, Xiu, Yuan, Rackoff (bib144) 2009; 27 Parri, Chiarugi (bib90) 2010; 8 Hedrick, Li, Safe (bib124) 2017; 16 Gewirtz (bib140) 1999; 57 Katsuta, Yan, Nagahashi, Raza, Sturgill, Lyon, Rashid, Hait, Takabe (bib142) 2017; 219 Lai, Chiu, Huang (bib10) 2010; 24 Serra, Lapidari, Quaquarini, Tagliaferri, Sottotetti, Palumbo (bib56) 2019; 8 Tuan, Lee (bib121) 2019; 24 Woditschka, Haag, Mau, Lubet, Gould (bib74) 2008; 10 (Accessed October 9, 2021). Kern, Schubert, Sahi, Schöneweiss, Moll, Haugg, Dienes, Breuhahn, Schirmacher (bib77) 2002; 36 Kalalinia, Elahian, Behravan (bib86) 2011; 137 Dhingra (bib130) 1999; 17 Coates, Winer, Goldhirsch, Gelber, Gnant, Piccart-Gebhart, Thürlimann, Senn (bib51) 2015; 26 Xia, Zhao, Lv, Xu, Shi, Wang, Han, Sun (bib87) 2009; 108 Wang, He, Feng, Cheng, Luo, Tian, Huang (bib93) 2003; 289 Pantziarka, Bouche, Meheus, Sukhatme, Sukhatme, Vikas (bib148) 2014; 8 Roberts, Peyman, Speirs (bib27) 2019; 1152 Watanabe, Oba, Tanimoto, Shibata, Kamijo, Ito (bib97) 2021; 16 Brand, Sawyer, King, Bolton, Fuhrman (bib52) 2000; 180 Balahura, Dinescu, Balaș, Cernencu, Lungu, Vlăsceanu, Iovu, Costache (bib96) 2021; 13 Xu, Chen, Li, Mao, Tang, Zhang, Ding, Tang (bib69) 2019; 10 Horiuchi, HoriuchiImai, Wang, Ohira, Feng, Nikaido, Konishi (bib91) 2003; 83 Okabe, Unno, Harigae, Kaku, Okitsu, Sasaki, Mizoi, Shiiba, Takanaga, Terasaki, Matsuno, Sasaki, Ito, Abe (bib139) 2005; 333 Prasad, Gupta, Aggarwal (bib3) 2016; 37 Baumann, Klusmeier, Eggemann, Reinartz, Almeroth, Kalder, Wagner (bib82) 2009; 3 Dean, Fojo, Bates (bib32) 2005; 5 M. Eriksson, M. Eklund, S. Borgquist, R. Hellgren, S. Margolin, L. Thoren, A. Rosendahl, K. Lång, J. Tapia, M. Bäcklund, A. Discacciati, A. Crippa, M. Gabrielson, M. Hammarström, Y. Wengström, K. Czene, P. Hall, Low-dose tamoxifen for mammographic density reduction: a randomized controlled trial, Https://Doi.Org/10.1200/JCO.20.02598 39, (2021) 1899–1908. . Wahdan-Alaswad, Thor (bib109) 2020 Joshi, Chakraborti, Ramirez-Vick, Ansari, Shanker, Chakrabarti, Singh (bib15) 2012; 95 Lee, Yesilkanal, Wynne, Frankenberger, Liu, Yan, Elbaz, Rabe, Rustandy, Tiwari, Grossman, Hart, Kang, Sanderson, Andrade, Nomura, Bonini, Locasale, Rosner (bib111) 2019; 568 Martinez (bib154) 2020; 64 W. Cao, Celecoxib in breast cancer prevention and therapy, (2018) pp. 4653–4667. Arnaout, Robertson, Pond, Lee, Jeong, Ianni, Kroeger, Hilton, Coupland, Gottlieb, Hurley, McCarthy, Clemons (bib14) 2019; 178 Hurle, Yang, Xie, Rajpal, Sanseau, Agarwal (bib46) 2013; 93 Roshan, Shing, Pace (bib102) 2019; 7 Xu, Chen, Jia, Tian, Dai, Li, Xie, Tao, Mao (bib101) 2015; 20 Allocati, Masulli, Di Ilio, Federici (bib36) 2018; 7 Kalalinia, Elahian, Mosaffa, Behravan (bib84) 2014; 13 Hernández-Lemus, Martínez-García (bib13) 2021; 0 (Accessed July 2, 2021). Fisher, Costantino, Wickerham, Cecchini, Cronin, Robidoux, Bevers, Kavanah, Atkins, Margolese, Runowicz, James, Ford, Wolmark (bib134) 2005; 97 Fife, Stott, Carr (bib83) 2004; 3 Verbaanderd, Rooman, Meheus, Huys (bib146) 2020; 0 Varalda, Antona, Bettio, Roy, Vachamaram, Yellenki, Massarotti, Baldanzi, Capello (bib126) 2020; 0 Waks, Winer (bib11) 2019; 321 Correia, Gärtner, Vale (bib2) 2021; 7 Li, Hao, Cao, Vadgama, Wu (bib81) 2018; 10 Nagaraj, Wang, Joseph, Zheng, Chen, Kovalenko, Singh, Armstrong, Resnick, Zanotti, Waggoner, Xu, DiFeo (bib43) 2018; 37 Gupta, Gupta, Srivastava (bib123) 2019; 9 Srivastava, Zahra, Gupta, Tullar, Srivastava, Mikelis (bib127) 2020; 21 Perroud, Alasino, Rico, Mainetti, Queralt, Pezzotto, Rozados, Scharovsky (bib53) 2016; 77 Pushpakom, Iorio, Eyers, Escott, Hopper, Wells, Doig, Guilliams, Latimer, McNamee, Norris, Sanseau, Cavalla, Pirmohamed (bib18) 2018; 18 Saxena, Sharma, Purohit (bib75) 2020; 147 Sorokin (bib85) 2004; 10 Shim, Matsui, Bhat, Nacev, Xu, Bhang, Dhara, Han, Chong, Pomper, So, Liu (bib116) 2010; 102 Home - ClinicalTrials.gov, (n.d.). Zhang, Zhou, Xie, Nice, Zhang, Cui, Huang (bib149) 2020; 5 Pappas, Jordan (bib59) 2001; 1 Jin, Hong, Choi, Maeng, Kim, Chung, Shim (bib105) 2009; 26 Sedlacek (bib68) 1993; 50 Ishida, Konishi, Ebner, Springer (bib4) 2016; 14 E.E. Kim, M. Yukihiro, Breast cancer, in: Clin. PET PET/CT Princ. Appl., (2013): pp. 227–233. J. W (bib64) 2001; 85 Haberkorn (bib7) 2007; 62 Mullard (bib21) 2021; 20 Dar, Johansson, Nordenskjöld, Iftimi, Yau, Perez-Tenorio, Benz, Nordenskjöld, Stål, Esserman, Fornander, Lindström (bib136) 2021; 4 Turnbull, Rahman (bib48) 2008; 9 Entezar-Almahdi, Mohammadi-Samani, Tayebi, Farjadian (bib94) 2020; 15 Lazovic, Guo, Nakashima, Mirsadraei, Yong, Kim, Ellingson, Wu, Pope (bib118) 2015; 17 Eggemann, Brucker, Schrauder, Thill, Flock, Reinisch, Costa, Ignatov (bib133) 2020; 123 Slotkin, Zhang, Dancel, Garcia, Willis, Seidler (bib17) 2000; 60 Saraei, Asadi, Kakar, Moradi-Kor (bib114) 2019; 11 Wicki, Witzigmann, Balasubramanian, Huwyler (bib41) 2015; 200 Simon, Weaver, Graham, Kivitz, Lipsky, Hubbard, Isakson, Verburg, Yu, Zhao, Geis (bib78) 1999; 282 Curry, Besmer, Erick, Steuerwald, Das Roy, Grover, Rao, Nath, Ferrier, Reid, Mukherjee (bib80) 2019; 14 Junttila, Sauvage (bib35) 2013; 501 Jones, Gee, Taylor, Barrow, Williams, Rubini, Nicholson (bib47) 2005; 12 Niraparib - List Results - ClinicalTrials.gov, Www.Clinicaltrials.Gov. (n.d.). Vogel, Johnston, Capers, Braccia (bib58) 2014; 14 Faria, Negalha, Azevedo, Martel (bib110) 2019; 24 Gómez del Pulgar, Benitah, Valerón, Espina, Lacal (bib89) 2005; 27 Cudkowicz, Titus, Kearney, Yu, Sherman, Schoenfeld, Hayden, Shui, Brooks, Conwit, Felsenstein, Greenblatt, Keroack, Kissel, Miller, Rosenfeld, Rothstein, Simpson, Tolkoff-Rubin, Zinman, Shefner (bib151) 2014; 13 Wang, Zhang, Chen (bib30) 2019; 2 Jordan (bib57) 1993; 110 Lee, Saiful Yazan, Che Abdullah (bib38) 2017; 12 Biotechnology Innovation Organization, Clinical development success rates and contributing factors 2011–2020, (2021) 1–34. Gonzalez-Angulo, Morales-Vasquez, Hortobagyi (bib31) 2007; 608 Hsieh Li, Liu, Chang, Ho, Huang (bib106) 2018; 25 Shim, Liu (bib115) 2014; 10 Dewangan, Srivastava, Mishra, Divakar, Kumar, Rath (bib16) 2019; 164 Nosengo (bib19) 2016; 534 Sparano, Wang, Martino, Jones, Perez, Saphner, Wolff, Sledge, Wood, Davidson (bib67) 2008; 358 V. Hanf, R. Kreienberg, WHO report on cancer, (2020). EC (bib147) 2014 Ranjan, Gupta, Srivastava (bib122) 2016; 76 Chahal, Stopeck, Clarke, Livingston, Chalasani (bib54) 2015; 36 Kapke, Schneidewend, Jawa, Huang, Connelly, Chitambar (bib73) 2019; 12 Hadad, Iwamoto, Jordan, Purdie, Bray, Baker, Jellema, Deharo, Hardie, Pusztai, Moulder-Thompson, Dewar, Thompson (bib103) 2011; 128 Yao, Deng, Huang, Zeng, Zuo (bib128) 2020; 11 Sodani, Patel, Kathawala, Chen (bib33) 2012; 31 Mokbel (bib62) 2003; 19 Chen, Shen, Yang, Chen, Xu (bib88) 2011; 137 Li, Shu (bib34) 2014; 2 Al-Batran, Bischoff, Von Minckwitz, Atmaca, Kleeberg, Meuthen, Morack, Lerbs, Hecker, Sehouli, Knuth, Jager (bib143) 2006; 94 Mirković, Markelc, Butinar, Mitrović, Sosič, Gobec, Vasiljeva, Turk, Čemažar, Serša, Kos (bib120) 2015; 6 Wang, He, Feng, Cheng, Luo, Tian, Huang (bib98) 2017; 11 Chidambaram, Manavalan, Kathiresan (bib39) 2011; 14 Gupta, Gupta, Srivastava (bib125) 2019; 9 Banno, Iida, Yanokura, Irie, Masuda, Kobayashi, Tominaga, Aoki (bib5) 2015; 2015 Gao, Shang, Li, Guo, Stojadinovic, Mannion, Man, Chen (bib119) 2020; 11 Shi, Hu, He, Fang (bib112) 2021; 22 Zhuang, Miskimins (bib107) 2008; 3 Aggarwal, Verma, Aggarwal, Gupta (bib1) 2021; 68 Galizia, Milani, Geuna, Martinello, Cagnazzo, Foresto, Longo, Berchialla, Solinas, Calori, Grasso, Volpone, Bertola, Parola, Tealdi, Giuliano, Ballari, Aglietta, Montemurro (bib42) 2018; 7 Luo, Zhao, Zhou, Yang, Zhang, Kuang, Peng, Chen, Zeng (bib44) 2017; 8 Sethy, Kundu (bib95) 2021; 137 Bikiaris, Papageorgiou, Stergiou, Pavlidou, Karavas, Kanaze, Georgarakis (bib40) 2005; 439 Costa, Amorim, Gärtner, Vale (bib26) 2020; 151 Morita, Leslie, Kameyama, Volk, Tanaka (bib28) 2018; 10 Fitzner, Oteng-Mensah (bib22) 2019; 171 Shu, Sheardown, Brown, Owen, Zhang, Castro, Ianculescu, Yue, Lo, Burchard, Brett, Giacomini (bib104) 2007; 117 Bekele, Venkatraman, Liu, Tang, Mi, Benesch, Mackey, Godbout, Curtis, McMullen, Brindley (bib132) 2016; 6 Zhang, Wu, Su, Gao, Meng, Sun, Li, Zhou, Zhou (bib55) 2012; 7 Royce, Osman (bib65) 2015; 9 Palve, Liao, Remsing Rix, Rix (bib45) 2021; 68 Lyseng-Williamson, Fenton (bib66) 2005; 65 Doroshow (bib141) 1986; 83 Wise (bib135) 2016; 355 Anjum, Razvi, Masood (bib8) 2017; 1 Boér (bib63) 2017; 9 Leng, Han, Demetris, Michalopoulos, Wu (bib76) 2003; 38 Anastasiadi, Lianos, Ignatiadou, Harissis, Mitsis (bib9) 2017; 69 Cree, Charlton (bib29) 2017; 17 Hurtado, Holmes, Geistlinger, Hutcheson, Nicholson, Brown, Jiang, Howat, Ali, Carroll (bib129) 2008; 456 VC (bib131) 2003; 2 Crockett, Schectman, Stürmer, Kappelman (bib152) 2014; 59 Khallaf, Roshdy, Ibrahim (bib145) 2020; 32 Robinson (bib50) 2020 Zhu, Davis, Blackwelder, Bachman, Liu, Edgerton, Williams, Thor, Yang (bib108) 2014; 7 Jiang, Taggart, Zhang, Benbrook, Lind, Ding (bib117) 2011; 312 Hazlehurst, Landowski, Dalton (bib37) 2003; 22 Chlebowski, McTiernan, Wactawski-Wende, Manson, Aragaki, Rohan, Ipp, Kaklamani, Vitolins, Wallace, Gunter, Phillips, Strickler, Margolis, Euhus (bib100) 2012; 30 Osaki, Tatebe, Goto, Hayashi, Oshimura, Ito (bib92) 1997; 2 Ávalos-Moreno, López-Tejada, Blaya-Cánovas, Cara-Lupiañez, González-González, Lorente, Sánchez-Rovira, Granados-Principal (bib6) 2020; 10 Gupta, Sung, Prasad, Webb, Aggarwal (bib12) 2013; 34 Johnson-Arbor, Dubey (bib138) 2020 de Gregorio, Häberle, Fasching, Müller, Schrader, Lorenz, Forstbauer, Friedl, Bauer, de Gregorio, Deniz, Fink, Bekes, Andergassen, Schneeweiss, Tesch, Mahner, Brucker, Blohmer, Fehm, Heinrich, Lato, Beckmann, Rack, Janni (bib72) 2020; 22 Goss, Ingle, Alés-Martínez, Cheung, Chlebowski, Wactawski-Wende, McTiernan, Robbins, Johnson, Martin, Winquist, Sarto, Garber, Fabian, Pujol, Maunsell, Farmer, Gelmon, Tu, Richardson (bib60) 2011; 364 Jiralerspong, Goodwin (bib99) 2016; 34 Longl Khallaf (10.1016/j.biopha.2021.112375_bib145) 2020; 32 Zhuang (10.1016/j.biopha.2021.112375_bib107) 2008; 3 Saraei (10.1016/j.biopha.2021.112375_bib114) 2019; 11 Allocati (10.1016/j.biopha.2021.112375_bib36) 2018; 7 Pushpakom (10.1016/j.biopha.2021.112375_bib18) 2018; 18 Balahura (10.1016/j.biopha.2021.112375_bib96) 2021; 13 Anastasiadi (10.1016/j.biopha.2021.112375_bib9) 2017; 69 Chahal (10.1016/j.biopha.2021.112375_bib54) 2015; 36 Correia (10.1016/j.biopha.2021.112375_bib2) 2021; 7 Lee (10.1016/j.biopha.2021.112375_bib38) 2017; 12 EC (10.1016/j.biopha.2021.112375_bib147) 2014 Banno (10.1016/j.biopha.2021.112375_bib5) 2015; 2015 Wahdan-Alaswad (10.1016/j.biopha.2021.112375_bib109) 2020 Kern (10.1016/j.biopha.2021.112375_bib77) 2002; 36 Shi (10.1016/j.biopha.2021.112375_bib112) 2021; 22 Jiralerspong (10.1016/j.biopha.2021.112375_bib99) 2016; 34 Vogel (10.1016/j.biopha.2021.112375_bib58) 2014; 14 Martinez (10.1016/j.biopha.2021.112375_bib153) 2021; 12 Zhang (10.1016/j.biopha.2021.112375_bib55) 2012; 7 Gewirtz (10.1016/j.biopha.2021.112375_bib140) 1999; 57 Zhang (10.1016/j.biopha.2021.112375_bib149) 2020; 5 Tuan (10.1016/j.biopha.2021.112375_bib121) 2019; 24 Bikiaris (10.1016/j.biopha.2021.112375_bib40) 2005; 439 Zhang (10.1016/j.biopha.2021.112375_bib113) 2020; 2020 51 Lazovic (10.1016/j.biopha.2021.112375_bib118) 2015; 17 Hernández-Lemus (10.1016/j.biopha.2021.112375_bib13) 2021; 0 Entezar-Almahdi (10.1016/j.biopha.2021.112375_bib94) 2020; 15 Ranjan (10.1016/j.biopha.2021.112375_bib122) 2016; 76 Gómez del Pulgar (10.1016/j.biopha.2021.112375_bib89) 2005; 27 Hsieh Li (10.1016/j.biopha.2021.112375_bib106) 2018; 25 Lee (10.1016/j.biopha.2021.112375_bib111) 2019; 568 Ávalos-Moreno (10.1016/j.biopha.2021.112375_bib6) 2020; 10 Nagaraj (10.1016/j.biopha.2021.112375_bib43) 2018; 37 Joshi (10.1016/j.biopha.2021.112375_bib15) 2012; 95 Gao (10.1016/j.biopha.2021.112375_bib119) 2020; 11 Crockett (10.1016/j.biopha.2021.112375_bib152) 2014; 59 Li (10.1016/j.biopha.2021.112375_bib34) 2014; 2 Haberkorn (10.1016/j.biopha.2021.112375_bib7) 2007; 62 Baumann (10.1016/j.biopha.2021.112375_bib82) 2009; 3 Al-Batran (10.1016/j.biopha.2021.112375_bib143) 2006; 94 Goss (10.1016/j.biopha.2021.112375_bib60) 2011; 364 Ishida (10.1016/j.biopha.2021.112375_bib4) 2016; 14 Dewangan (10.1016/j.biopha.2021.112375_bib16) 2019; 164 Xia (10.1016/j.biopha.2021.112375_bib87) 2009; 108 Roshan (10.1016/j.biopha.2021.112375_bib102) 2019; 7 Roberts (10.1016/j.biopha.2021.112375_bib27) 2019; 1152 Sorokin (10.1016/j.biopha.2021.112375_bib85) 2004; 10 Eggemann (10.1016/j.biopha.2021.112375_bib133) 2020; 123 Anjum (10.1016/j.biopha.2021.112375_bib8) 2017; 1 VC (10.1016/j.biopha.2021.112375_bib131) 2003; 2 Lyseng-Williamson (10.1016/j.biopha.2021.112375_bib66) 2005; 65 Gupta (10.1016/j.biopha.2021.112375_bib123) 2019; 9 Martinez (10.1016/j.biopha.2021.112375_bib154) 2020; 64 He (10.1016/j.biopha.2021.112375_bib61) 2016; 9 10.1016/j.biopha.2021.112375_bib49 Katsuta (10.1016/j.biopha.2021.112375_bib142) 2017; 219 Pantziarka (10.1016/j.biopha.2021.112375_bib148) 2014; 8 Zhu (10.1016/j.biopha.2021.112375_bib108) 2014; 7 Chen (10.1016/j.biopha.2021.112375_bib88) 2011; 137 Jordan (10.1016/j.biopha.2021.112375_bib57) 1993; 110 Mullard (10.1016/j.biopha.2021.112375_bib21) 2021; 20 Wang (10.1016/j.biopha.2021.112375_bib98) 2017; 11 Varalda (10.1016/j.biopha.2021.112375_bib126) 2020; 0 Mokbel (10.1016/j.biopha.2021.112375_bib62) 2003; 19 J. W (10.1016/j.biopha.2021.112375_bib64) 2001; 85 Kalalinia (10.1016/j.biopha.2021.112375_bib86) 2011; 137 Serra (10.1016/j.biopha.2021.112375_bib56) 2019; 8 Gupta (10.1016/j.biopha.2021.112375_bib12) 2013; 34 Nosengo (10.1016/j.biopha.2021.112375_bib19) 2016; 534 Doroshow (10.1016/j.biopha.2021.112375_bib141) 1986; 83 Perroud (10.1016/j.biopha.2021.112375_bib53) 2016; 77 Curry (10.1016/j.biopha.2021.112375_bib80) 2019; 14 Bekele (10.1016/j.biopha.2021.112375_bib132) 2016; 6 Fitzner (10.1016/j.biopha.2021.112375_bib22) 2019; 171 Wang (10.1016/j.biopha.2021.112375_bib93) 2003; 289 Wicki (10.1016/j.biopha.2021.112375_bib41) 2015; 200 Sparano (10.1016/j.biopha.2021.112375_bib144) 2009; 27 Gupta (10.1016/j.biopha.2021.112375_bib125) 2019; 9 10.1016/j.biopha.2021.112375_bib20 Jiang (10.1016/j.biopha.2021.112375_bib117) 2011; 312 Boér (10.1016/j.biopha.2021.112375_bib63) 2017; 9 Aggarwal (10.1016/j.biopha.2021.112375_bib1) 2021; 68 Li (10.1016/j.biopha.2021.112375_bib81) 2018; 10 Horiuchi (10.1016/j.biopha.2021.112375_bib91) 2003; 83 Fisher (10.1016/j.biopha.2021.112375_bib134) 2005; 97 Morita (10.1016/j.biopha.2021.112375_bib28) 2018; 10 Shu (10.1016/j.biopha.2021.112375_bib104) 2007; 117 Waks (10.1016/j.biopha.2021.112375_bib11) 2019; 321 Kalalinia (10.1016/j.biopha.2021.112375_bib84) 2014; 13 Jin (10.1016/j.biopha.2021.112375_bib105) 2009; 26 10.1016/j.biopha.2021.112375_bib137 Brand (10.1016/j.biopha.2021.112375_bib52) 2000; 180 Palve (10.1016/j.biopha.2021.112375_bib45) 2021; 68 Parri (10.1016/j.biopha.2021.112375_bib90) 2010; 8 Lai (10.1016/j.biopha.2021.112375_bib10) 2010; 24 de Gregorio (10.1016/j.biopha.2021.112375_bib72) 2020; 22 Leng (10.1016/j.biopha.2021.112375_bib76) 2003; 38 Fife (10.1016/j.biopha.2021.112375_bib83) 2004; 3 Galizia (10.1016/j.biopha.2021.112375_bib42) 2018; 7 Hurtado (10.1016/j.biopha.2021.112375_bib129) 2008; 456 10.1016/j.biopha.2021.112375_bib23 10.1016/j.biopha.2021.112375_bib24 Wang (10.1016/j.biopha.2021.112375_bib30) 2019; 2 10.1016/j.biopha.2021.112375_bib25 Saxena (10.1016/j.biopha.2021.112375_bib75) 2020; 147 Junttila (10.1016/j.biopha.2021.112375_bib35) 2013; 501 Shim (10.1016/j.biopha.2021.112375_bib116) 2010; 102 Jones (10.1016/j.biopha.2021.112375_bib47) 2005; 12 Srivastava (10.1016/j.biopha.2021.112375_bib127) 2020; 21 Simon (10.1016/j.biopha.2021.112375_bib78) 1999; 282 Bezprozvanny (10.1016/j.biopha.2021.112375_bib150) 2010; 23 Gonzalez-Angulo (10.1016/j.biopha.2021.112375_bib31) 2007; 608 Dar (10.1016/j.biopha.2021.112375_bib136) 2021; 4 Turnbull (10.1016/j.biopha.2021.112375_bib48) 2008; 9 Yao (10.1016/j.biopha.2021.112375_bib128) 2020; 11 Cree (10.1016/j.biopha.2021.112375_bib29) 2017; 17 Longley (10.1016/j.biopha.2021.112375_bib70) 2003; 3 Sparano (10.1016/j.biopha.2021.112375_bib67) 2008; 358 Mirković (10.1016/j.biopha.2021.112375_bib120) 2015; 6 Slotkin (10.1016/j.biopha.2021.112375_bib17) 2000; 60 Hurle (10.1016/j.biopha.2021.112375_bib46) 2013; 93 Coates (10.1016/j.biopha.2021.112375_bib51) 2015; 26 10.1016/j.biopha.2021.112375_bib79 Prasad (10.1016/j.biopha.2021.112375_bib3) 2016; 37 Sethy (10.1016/j.biopha.2021.112375_bib95) 2021; 137 Chidambaram (10.1016/j.biopha.2021.112375_bib39) 2011; 14 Dhingra (10.1016/j.biopha.2021.112375_bib130) 1999; 17 Robinson (10.1016/j.biopha.2021.112375_bib50) 2020 Shim (10.1016/j.biopha.2021.112375_bib115) 2014; 10 Royce (10.1016/j.biopha.2021.112375_bib65) 2015; 9 Chlebowski (10.1016/j.biopha.2021.112375_bib100) 2012; 30 Cudkowicz (10.1016/j.biopha.2021.112375_bib151) 2014; 13 Hedrick (10.1016/j.biopha.2021.112375_bib124) 2017; 16 Pappas (10.1016/j.biopha.2021.112375_bib59) 2001; 1 Hazlehurst (10.1016/j.biopha.2021.112375_bib37) 2003; 22 Hadad (10.1016/j.biopha.2021.112375_bib103) 2011; 128 Dean (10.1016/j.biopha.2021.112375_bib32) 2005; 5 Wise (10.1016/j.biopha.2021.112375_bib135) 2016; 355 Verbaanderd (10.1016/j.biopha.2021.112375_bib146) 2020; 0 Sodani (10.1016/j.biopha.2021.112375_bib33) 2012; 31 Faria (10.1016/j.biopha.2021.112375_bib110) 2019; 24 Johnson-Arbor (10.1016/j.biopha.2021.112375_bib138) 2020 Arnaout (10.1016/j.biopha.2021.112375_bib14) 2019; 178 Luo (10.1016/j.biopha.2021.112375_bib44) 2017; 8 Ponce-Cusi (10.1016/j.biopha.2021.112375_bib71) 2016; 48 Kapke (10.1016/j.biopha.2021.112375_bib73) 2019; 12 Woditschka (10.1016/j.biopha.2021.112375_bib74) 2008; 10 Osaki (10.1016/j.biopha.2021.112375_bib92) 1997; 2 Xu (10.1016/j.biopha.2021.112375_bib101) 2015; 20 Okabe (10.1016/j.biopha.2021.112375_bib139) 2005; 333 Watanabe (10.1016/j.biopha.2021.112375_bib97) 2021; 16 Costa (10.1016/j.biopha.2021.112375_bib26) 2020; 151 Xu (10.1016/j.biopha.2021.112375_bib69) 2019; 10 Sedlacek (10.1016/j.biopha.2021.112375_bib68) 1993; 50 |
| References_xml | – reference: Biotechnology Innovation Organization, Clinical development success rates and contributing factors 2011–2020, (2021) 1–34. – volume: 9 start-page: 465 year: 2017 end-page: 479 ident: bib63 article-title: Fulvestrant in advanced breast cancer: evidence to date and place in therapy publication-title: Ther. Adv. Med. Oncol. – reference: M. Eriksson, M. Eklund, S. Borgquist, R. Hellgren, S. Margolin, L. Thoren, A. Rosendahl, K. Lång, J. Tapia, M. Bäcklund, A. Discacciati, A. Crippa, M. Gabrielson, M. Hammarström, Y. Wengström, K. Czene, P. Hall, Low-dose tamoxifen for mammographic density reduction: a randomized controlled trial, Https://Doi.Org/10.1200/JCO.20.02598 39, (2021) 1899–1908. – volume: 27 start-page: 602 year: 2005 end-page: 613 ident: bib89 article-title: Rho GTPase expression in tumourigenesis: evidence for a significant link publication-title: Bioessays – volume: 8 start-page: 1 year: 2019 end-page: 16 ident: bib56 article-title: Palbociclib in metastatic breast cancer: current evidence and real-life data publication-title: Drugs Context – volume: 83 start-page: 861 year: 2003 end-page: 870 ident: bib91 article-title: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma publication-title: Lab. Investig. – volume: 10 start-page: 200 year: 2020 ident: bib6 article-title: Drug repurposing for triple-negative breast cancer publication-title: J. Pers. Med. – volume: 22 start-page: 1 year: 2020 end-page: 11 ident: bib72 article-title: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-a trial publication-title: Breast Cancer Res. – volume: 16 year: 2021 ident: bib97 article-title: Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer publication-title: PLoS One – volume: 12 start-page: 189 year: 2019 end-page: 193 ident: bib73 article-title: High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: case series and review of the literature publication-title: Hematol. Oncol. Stem Cell Ther. – volume: 14 year: 2019 ident: bib80 article-title: Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice publication-title: PLoS One – volume: 6 start-page: 19027 year: 2015 ident: bib120 article-title: Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity publication-title: Oncotarget – volume: 13 start-page: 1083 year: 2014 end-page: 1091 ident: bib151 article-title: Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial publication-title: Lancet Neurol. – volume: 15 start-page: 5445 year: 2020 end-page: 5458 ident: bib94 article-title: Recent advances in designing 5-fluorouracil delivery systems: a stepping stone in the safe treatment of colorectal cancer publication-title: Int. J. Nanomed. – volume: 1152 start-page: 413 year: 2019 end-page: 427 ident: bib27 article-title: Current and emerging 3D models to study breast cancer publication-title: Adv. Exp. Med. Biol. – volume: 9 start-page: 73 year: 2015 ident: bib65 article-title: Everolimus in the treatment of metastatic breast cancer publication-title: Breast Cancer – volume: 321 start-page: 288 year: 2019 end-page: 300 ident: bib11 article-title: Breast cancer treatment: a review publication-title: JAMA J. Am. Med. Assoc. – volume: 108 start-page: 181 year: 2009 end-page: 194 ident: bib87 article-title: Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner publication-title: J. Cell. Biochem. – volume: 97 start-page: 1652 year: 2005 end-page: 1662 ident: bib134 article-title: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study publication-title: J. Natl. Cancer Inst. – volume: 11 start-page: 2421 year: 2017 end-page: 2429 ident: bib98 article-title: Metformin: a review of its potential indications publication-title: Drug Des. Dev. Ther. – volume: 9 year: 2019 ident: bib125 article-title: Penfluridol overcomes paclitaxel resistance in metastatic breast cancer publication-title: Sci. Rep. – volume: 3 year: 2008 ident: bib107 article-title: Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 publication-title: J. Mol. Signal. – volume: 164 start-page: 326 year: 2019 end-page: 335 ident: bib16 article-title: Salinomycin inhibits breast cancer progression via targeting HIF-1α/VEGF mediated tumor angiogenesis in vitro and in vivo publication-title: Biochem. Pharmacol. – volume: 17 start-page: 53 year: 2015 end-page: 62 ident: bib118 article-title: Nitroxoline induces apoptosis and slows glioma growth in vivo publication-title: Neuro Oncol. – volume: 11 start-page: 5135 year: 2020 end-page: 5149 ident: bib119 article-title: Antibiotics for cancer treatment: a double-edged sword publication-title: J. Cancer – volume: 3 start-page: 330 year: 2003 end-page: 338 ident: bib70 article-title: 5-fluorouracil: mechanisms of action and clinical strategies publication-title: Nat. Rev. Cancer – volume: 68 start-page: 209 year: 2021 end-page: 229 ident: bib45 article-title: Turning liabilities into opportunities: off-target based drug repurposing in cancer publication-title: Semin. Cancer Biol. – volume: 23 start-page: 518 year: 2010 end-page: 523 ident: bib150 article-title: The rise and fall of Dimebon publication-title: Drug News Perspect. – volume: 312 start-page: 11 year: 2011 end-page: 17 ident: bib117 article-title: Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline) publication-title: Cancer Lett. – volume: 16 start-page: 205 year: 2017 end-page: 216 ident: bib124 article-title: Penfluridol represses integrin expression in breast cancer through induction of reactive oxygen species and downregulation of Sp transcription factors publication-title: Mol. Cancer Ther. – volume: 180 start-page: 424 year: 2000 end-page: 427 ident: bib52 article-title: Understanding patterns of failure in breast cancer treatment argues for a more thorough investigation of axillary lymph nodes in node negative patients publication-title: Am. J. Surg. – volume: 2 start-page: 15 year: 2014 ident: bib34 article-title: Role of solute carriers in response to anticancer drugs publication-title: Mol. Cell. Ther. – volume: 10 start-page: 4653 year: 2018 end-page: 4667 ident: bib81 article-title: Celecoxib in breast cancer prevention and therapy publication-title: Cancer Manag. Res. – volume: 0 start-page: 1664 year: 2020 ident: bib146 article-title: On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients publication-title: Front. Pharmacol. – reference: Niraparib - List Results - ClinicalTrials.gov, Www.Clinicaltrials.Gov. (n.d.). – volume: 10 start-page: 654 year: 2014 end-page: 663 ident: bib115 article-title: Recent advances in drug repositioning for the discovery of new anticancer drugs publication-title: Int. J. Biol. Sci. – volume: 358 start-page: 1663 year: 2008 ident: bib67 article-title: Weekly paclitaxel in the adjuvant treatment of breast cancer publication-title: N. Engl. J. Med. – volume: 34 start-page: 508 year: 2013 end-page: 517 ident: bib12 article-title: Cancer drug discovery by repurposing: teaching new tricks to old dogs publication-title: Trends Pharmacol. Sci. – volume: 48 start-page: 774 year: 2016 end-page: 782 ident: bib71 article-title: Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation publication-title: Int. J. Oncol. – volume: 219 start-page: 202 year: 2017 end-page: 213 ident: bib142 article-title: Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer publication-title: J. Surg. Res. – volume: 31 start-page: 58 year: 2012 end-page: 72 ident: bib33 article-title: Multidrug resistance associated proteins in multindrung resistance publication-title: Chin. J. Cancer – volume: 50 start-page: 16 year: 1993 end-page: 23 ident: bib68 article-title: First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine publication-title: Oncology – volume: 137 start-page: 9 year: 2011 end-page: 17 ident: bib88 article-title: Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib publication-title: J. Cancer Res. Clin. Oncol. – volume: 27 start-page: 4522 year: 2009 end-page: 4529 ident: bib144 article-title: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study publication-title: J. Clin. Oncol. – volume: 178 start-page: 327 year: 2019 end-page: 335 ident: bib14 article-title: A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients publication-title: Breast Cancer Res. Treat. – volume: 364 start-page: 2381 year: 2011 end-page: 2391 ident: bib60 article-title: Exemestane for breast-cancer prevention in postmenopausal women publication-title: N. Engl. J. Med. – volume: 123 start-page: 33 year: 2020 end-page: 37 ident: bib133 article-title: Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis publication-title: Br. J. Cancer – volume: 117 start-page: 1422 year: 2007 end-page: 1431 ident: bib104 article-title: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action publication-title: J. Clin. Investig. – volume: 137 year: 2021 ident: bib95 article-title: 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition publication-title: Biomed. Pharmacother. – volume: 2020 51 start-page: 1 year: 2020 end-page: 25 ident: bib113 article-title: Overcoming cancer therapeutic bottleneck by drug repurposing publication-title: Signal Transduct. Target. Ther. – volume: 9 start-page: 1077 year: 2016 ident: bib61 article-title: Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective publication-title: Onco Targets Ther. – volume: 10 start-page: 647 year: 2004 end-page: 657 ident: bib85 article-title: Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype publication-title: Curr. Pharm. Des. – volume: 36 start-page: 1691 year: 2015 end-page: 1693 ident: bib54 article-title: Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series publication-title: Neurol. Sci. – reference: Home - ClinicalTrials.gov, (n.d.). 〈 – volume: 3 start-page: 23 year: 2009 end-page: 34 ident: bib82 article-title: Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro publication-title: Breast Cancer – volume: 568 start-page: 254 year: 2019 end-page: 258 ident: bib111 article-title: Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism publication-title: Nature – volume: 93 start-page: 335 year: 2013 end-page: 341 ident: bib46 article-title: Computational drug repositioning: from data to therapeutics publication-title: Clin. Pharmacol. Ther. – reference: 〉. (Accessed October 9, 2021). – volume: 12 year: 2021 ident: bib153 article-title: Lack of effectiveness of repurposed drugs for COVID-19 treatment publication-title: Front. Immunol. – volume: 22 start-page: 7396 year: 2003 end-page: 7402 ident: bib37 article-title: Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death publication-title: Oncogene – volume: 59 start-page: 1535 year: 2014 end-page: 1543 ident: bib152 article-title: Topiramate use does not reduce flares of inflammatory bowel disease publication-title: Dig. Dis. Sci. – volume: 0 start-page: 2148 year: 2020 ident: bib126 article-title: Psychotropic drugs show anticancer activity by disrupting mitochondrial and lysosomal function publication-title: Front. Oncol. – volume: 200 start-page: 138 year: 2015 end-page: 157 ident: bib41 article-title: Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications publication-title: J. Control. Release – volume: 18 start-page: 41 year: 2018 end-page: 58 ident: bib18 article-title: Drug repurposing: progress, challenges and recommendations publication-title: Nat. Rev. Drug Discov. – volume: 14 start-page: 67 year: 2011 end-page: 77 ident: bib39 article-title: Nanotherapeutics to overcome conventional cancer chemotherapy limitations publication-title: J. Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci. Soc. Can. Des. Sci. Pharm. – volume: 24 start-page: 3659 year: 2019 ident: bib121 article-title: Penfluridol as a candidate of drug repurposing for anticancer agent publication-title: Molecules – volume: 151 year: 2020 ident: bib26 article-title: Understanding Breast cancer: from conventional therapies to repurposed drugs publication-title: Eur. J. Pharm. Sci. – volume: 38 start-page: 756 year: 2003 end-page: 768 ident: bib76 article-title: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis publication-title: Hepatology – volume: 69 start-page: 313 year: 2017 end-page: 317 ident: bib9 article-title: Breast cancer in young women: an overview publication-title: Updates Surg. – volume: 355 year: 2016 ident: bib135 article-title: Tamoxifen benefits women who have had invasive breast cancer, community study finds publication-title: BMJ – volume: 6 year: 2016 ident: bib132 article-title: Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance publication-title: Sci. Rep. – reference: V. Hanf, R. Kreienberg, WHO report on cancer, (2020). 〈 – volume: 37 start-page: 435 year: 2016 end-page: 450 ident: bib3 article-title: Serendipity in cancer drug discovery: rational or coincidence? publication-title: Trends Pharmacol. Sci. – volume: 13 year: 2021 ident: bib96 article-title: Cellulose nanofiber-based hydrogels embedding 5-FU promote pyroptosis activation in breast cancer cells and support human adipose-derived stem cell proliferation, opening new perspectives for breast tissue engineering publication-title: Pharmaceutics – volume: 26 start-page: 1533 year: 2015 end-page: 1546 ident: bib51 article-title: Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. – volume: 83 start-page: 4514 year: 1986 end-page: 4518 ident: bib141 article-title: Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 60 start-page: 153 year: 2000 end-page: 166 ident: bib17 article-title: Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells publication-title: Breast Cancer Res. Treat. – volume: 94 start-page: 1615 year: 2006 end-page: 1620 ident: bib143 article-title: The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial publication-title: Br. J. Cancer – volume: 534 start-page: 314 year: 2016 end-page: 316 ident: bib19 article-title: Can you teach old drugs new tricks? publication-title: Nature – start-page: 1 year: 2020 end-page: 5 ident: bib138 article-title: Doxorubicin publication-title: XPharm Compr. Pharmacol. Ref. – volume: 57 start-page: 727 year: 1999 end-page: 741 ident: bib140 article-title: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin publication-title: Biochem. Pharmacol. – reference: W. Cao, Celecoxib in breast cancer prevention and therapy, (2018) pp. 4653–4667. – year: 2020 ident: bib109 article-title: Metformin activity against breast cancer: mechanistic differences by molecular subtype and metabolic conditions publication-title: Metformin [Work. Title] – volume: 20 start-page: 1236 year: 2015 end-page: 1244 ident: bib101 article-title: Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis publication-title: Oncologist – volume: 8 year: 2010 ident: bib90 article-title: Rac and Rho GTPases in cancer cell motility control publication-title: Cell Commun. Signal. – volume: 137 start-page: 321 year: 2011 end-page: 330 ident: bib86 article-title: Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines publication-title: J. Cancer Res. Clin. Oncol. – volume: 36 start-page: 885 year: 2002 end-page: 894 ident: bib77 article-title: Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells publication-title: Hepatology – volume: 8 start-page: 573 year: 2017 ident: bib44 article-title: A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information publication-title: Nat. Commun. – volume: 7 year: 2012 ident: bib55 article-title: Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer publication-title: PLoS One – reference: 〉. – volume: 64 year: 2020 ident: bib154 article-title: Clinical trials of repurposed antivirals for SARS-CoV-2 publication-title: Antimicrob. Agents Chemother. – volume: 8 year: 2014 ident: bib148 article-title: The repurposing drugs in oncology (ReDO) project publication-title: Ecancermedicalscience – volume: 7 start-page: 199 year: 2014 end-page: 210 ident: bib108 article-title: Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models publication-title: Cancer Prev. Res. – start-page: 1 year: 2014 end-page: 4 ident: bib147 article-title: Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the publication-title: Off. J. Eur. Union – volume: 1 start-page: 334 year: 2001 end-page: 340 ident: bib59 article-title: Raloxifene for the treatment and prevention of breast cancer? publication-title: Expert Rev. Anticancer Ther. – volume: 9 start-page: 1 year: 2019 end-page: 14 ident: bib123 article-title: Penfluridol overcomes paclitaxel resistance in metastatic breast cancer publication-title: Sci. Rep. – volume: 2015 year: 2015 ident: bib5 article-title: Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer publication-title: Sci. World J. – volume: 24 year: 2010 ident: bib10 article-title: Overexpression of BDNF and TrkB in human bladder cancer specimens publication-title: Oncol. Rep. – volume: 77 start-page: 365 year: 2016 end-page: 374 ident: bib53 article-title: Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response publication-title: Cancer Chemother. Pharmacol. – volume: 24 start-page: 111 year: 2019 end-page: 123 ident: bib110 article-title: Metformin and breast cancer: molecular targets publication-title: J. Mammary Gland Biol. Neoplasia. – volume: 11 start-page: 3295 year: 2019 end-page: 3313 ident: bib114 article-title: The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances publication-title: Cancer Manag. Res. – volume: 501 start-page: 346 year: 2013 end-page: 354 ident: bib35 article-title: Influence of tumour micro-environment heterogeneity on therapeutic response publication-title: Nature – volume: 21 start-page: 1 year: 2020 end-page: 14 ident: bib127 article-title: Low dose of penfluridol inhibits VEGF-induced angiogenesis publication-title: Int. J. Mol. Sci. – volume: 34 start-page: 4203 year: 2016 end-page: 4216 ident: bib99 article-title: Obesity and breast cancer prognosis: evidence, challenges, and opportunities publication-title: J. Clin. Oncol. – volume: 95 start-page: 195 year: 2012 end-page: 200 ident: bib15 article-title: The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells publication-title: Colloids Surf. B Biointerfaces – volume: 3 start-page: 228 year: 2004 end-page: 232 ident: bib83 article-title: Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro publication-title: Cancer Biol. Ther. – volume: 12 start-page: 2373 year: 2017 end-page: 2384 ident: bib38 article-title: A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment publication-title: Int. J. Nanomed. – volume: 14 start-page: 1 year: 2014 end-page: 9 ident: bib58 article-title: Toremifene for breast cancer: a review of 20 years of data publication-title: Clin. Breast Cancer – volume: 10 start-page: 418 year: 2019 end-page: 429 ident: bib69 article-title: Addition of capecitabine in breast cancer first-line chemotherapy improves survival of breast cancer patients publication-title: J. Cancer – volume: 0 start-page: 2996 year: 2021 ident: bib13 article-title: Pathway-based drug-repurposing schemes in cancer: the role of translational bioinformatics publication-title: Front. Oncol. – volume: 62 start-page: 1 year: 2007 end-page: 16 ident: bib7 article-title: What is cancer? publication-title: Adv. Nucl. Oncol. – volume: 439 start-page: 58 year: 2005 end-page: 67 ident: bib40 article-title: Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques publication-title: Thermochim. Acta – volume: 4 year: 2021 ident: bib136 article-title: Assessment of 25-year survival of women with estrogen receptor–positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: a secondary analysis of data from the stockholm tamoxifen randomized clinical trial publication-title: JAMA Netw. Open – volume: 147 year: 2020 ident: bib75 article-title: A journey of celecoxib from pain to cancer publication-title: Prostaglandins Other Lipid Mediat. – volume: 333 start-page: 754 year: 2005 end-page: 762 ident: bib139 article-title: Characterization of the organic cation transporter SLC22A16: a doxorubicin importer publication-title: Biochem. Biophys. Res. Commun. – volume: 2 start-page: 141 year: 2019 end-page: 160 ident: bib30 article-title: Drug resistance and combating drug resistance in cancer publication-title: Cancer Drug Resist. – volume: 65 start-page: 2513 year: 2005 end-page: 2531 ident: bib66 article-title: Docetaxel: a review of its use in metastatic breast cancer publication-title: Drugs – volume: 68 start-page: 8 year: 2021 end-page: 20 ident: bib1 article-title: Drug repurposing for breast cancer therapy: old weapon for new battle publication-title: Semin. Cancer Biol. – volume: 171 start-page: 1 year: 2019 end-page: 20 ident: bib22 article-title: Impact of cost on the safety of cancer pharmaceuticals publication-title: Cancer Treat. Res – volume: 2 start-page: 205 year: 2003 end-page: 213 ident: bib131 article-title: Tamoxifen: a most unlikely pioneering medicine publication-title: Nat. Rev. Drug Discov. – volume: 1 start-page: 35 year: 2017 end-page: 38 ident: bib8 article-title: Breast cancer therapy: a mini review publication-title: MOJ Drug Des. Dev. Ther. – volume: 14 start-page: 1 year: 2016 end-page: 15 ident: bib4 article-title: Repurposing of approved cardiovascular drugs publication-title: J. Transl. Med. – volume: 26 start-page: 549 year: 2009 end-page: 559 ident: bib105 article-title: Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis publication-title: Pharm. Res. – volume: 7 year: 2019 ident: bib102 article-title: Metformin as an adjuvant in breast cancer treatment publication-title: SAGE Open Med. – volume: 17 start-page: 1 year: 2017 end-page: 8 ident: bib29 article-title: Molecular chess? Hallmarks of anti-cancer drug resistance publication-title: BMC Cancer – volume: 37 start-page: 403 year: 2018 end-page: 414 ident: bib43 article-title: Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment publication-title: Oncogene – volume: 5 start-page: 1 year: 2020 end-page: 25 ident: bib149 article-title: Overcoming cancer therapeutic bottleneck by drug repurposing publication-title: Signal Transduct. Target. Ther. – volume: 7 start-page: 4339 year: 2018 end-page: 4344 ident: bib42 article-title: Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: a prospective study publication-title: Cancer Med. – volume: 282 start-page: 1921 year: 1999 end-page: 1928 ident: bib78 article-title: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial publication-title: JAMA – volume: 22 start-page: 1 year: 2021 end-page: 14 ident: bib112 article-title: Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2 publication-title: Oncol. Lett. – volume: 128 start-page: 783 year: 2011 end-page: 794 ident: bib103 article-title: Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial publication-title: Breast Cancer Res. Treat. – volume: 110 start-page: 507 year: 1993 end-page: 517 ident: bib57 article-title: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer publication-title: Br. J. Pharmacol. – volume: 30 start-page: 2844 year: 2012 end-page: 2852 ident: bib100 article-title: Diabetes, metformin, and breast cancer in postmenopausal women publication-title: J. Clin. Oncol. – volume: 456 start-page: 663 year: 2008 end-page: 666 ident: bib129 article-title: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen publication-title: Nature – volume: 19 start-page: 683 year: 2003 end-page: 688 ident: bib62 article-title: Focus on anastrozole and breast cancer publication-title: Curr. Med. Res. Opin. – reference: E.E. Kim, M. Yukihiro, Breast cancer, in: Clin. PET PET/CT Princ. Appl., (2013): pp. 227–233. 〈 – year: 2020 ident: bib50 article-title: Types of breast cancer: triple negative, ER-Positive, HER2-Positive publication-title: WebMD Med. Ref. – reference: (Accessed July 2, 2021). – volume: 85 start-page: 1 year: 2001 end-page: 5 ident: bib64 article-title: Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women publication-title: Br. J. Cancer – volume: 10 start-page: 1 year: 2008 end-page: 9 ident: bib74 article-title: Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model publication-title: Breast Cancer Res. – volume: 7 year: 2021 ident: bib2 article-title: Drug combination and repurposing for cancer therapy: the example of breast cancer publication-title: Heliyon – volume: 102 start-page: 1855 year: 2010 end-page: 1873 ident: bib116 article-title: Effect of nitroxoline on angiogenesis and growth of human bladder cancer publication-title: JNCI J. Natl. Cancer Inst. – volume: 32 start-page: 1 year: 2020 end-page: 10 ident: bib145 article-title: Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center publication-title: J. Egypt. Natl. Cancer Inst. – volume: 9 start-page: 321 year: 2008 end-page: 345 ident: bib48 article-title: Genetic predisposition to breast cancer: past, present, and future publication-title: Annu. Rev. Genom. Hum. Genet. – volume: 13 start-page: 1393 year: 2014 ident: bib84 article-title: Celecoxib up regulates the expression of drug efflux transporter ABCG2 in breast cancer cell lines publication-title: Iran. J. Pharm. Res. IJPR – volume: 25 year: 2018 ident: bib106 article-title: Metformin causes cancer cell death through downregulation of p53-dependent differentiated embryo chondrocyte 1 publication-title: J. Biomed. Sci. – volume: 17 start-page: 285 year: 1999 end-page: 311 ident: bib130 article-title: Antiestrogens--tamoxifen, SERMs and beyond publication-title: Investig. New Drugs – volume: 289 start-page: 27 year: 2003 end-page: 35 ident: bib93 article-title: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line publication-title: Exp. Cell Res. – reference: . – volume: 76 start-page: 877 year: 2016 end-page: 890 ident: bib122 article-title: Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in triple-negative breast cancer by inhibiting integrin signaling axis publication-title: Cancer Res. – volume: 5 start-page: 275 year: 2005 end-page: 284 ident: bib32 article-title: Tumour stem cells and drug resistance publication-title: Nat. Rev. Cancer – volume: 7 start-page: 8 year: 2018 ident: bib36 article-title: Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases publication-title: Oncogenesis – volume: 2 start-page: 221 year: 1997 end-page: 226 ident: bib92 article-title: 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene publication-title: Apoptosis – volume: 12 year: 2005 ident: bib47 article-title: Development of strategies for the use of anti-growth factor treatments publication-title: Endocr. Relat. Cancer – volume: 608 start-page: 1 year: 2007 end-page: 22 ident: bib31 article-title: Overview of resistance to systemic therapy in patients with breast cancer publication-title: Adv. Exp. Med. Biol. – volume: 20 start-page: 85 year: 2021 end-page: 90 ident: bib21 article-title: 2020 FDA drug approvals publication-title: Nat. Rev. Drug Discov. – volume: 10 year: 2018 ident: bib28 article-title: Aptamer therapeutics in cancer: current and future publication-title: Cancers – volume: 11 year: 2020 ident: bib128 article-title: Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer publication-title: Front. Pharmacol. – volume: 123 start-page: 33 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib133 article-title: Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis publication-title: Br. J. Cancer doi: 10.1038/s41416-020-0857-z – ident: 10.1016/j.biopha.2021.112375_bib24 – volume: 21 start-page: 1 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib127 article-title: Low dose of penfluridol inhibits VEGF-induced angiogenesis publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21030755 – volume: 4 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib136 article-title: Assessment of 25-year survival of women with estrogen receptor–positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: a secondary analysis of data from the stockholm tamoxifen randomized clinical trial publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2021.14904 – volume: 23 start-page: 518 issue: 8 year: 2010 ident: 10.1016/j.biopha.2021.112375_bib150 article-title: The rise and fall of Dimebon publication-title: Drug News Perspect. doi: 10.1358/dnp.2010.23.8.1500435 – volume: 2 start-page: 205 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib131 article-title: Tamoxifen: a most unlikely pioneering medicine publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd1031 – volume: 2015 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib5 article-title: Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer publication-title: Sci. World J. doi: 10.1155/2015/341362 – volume: 12 start-page: 2373 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib38 article-title: A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment publication-title: Int. J. Nanomed. doi: 10.2147/IJN.S127329 – volume: 17 start-page: 1 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib29 article-title: Molecular chess? Hallmarks of anti-cancer drug resistance publication-title: BMC Cancer doi: 10.1186/s12885-016-2999-1 – volume: 50 start-page: 16 issue: Suppl 1 year: 1993 ident: 10.1016/j.biopha.2021.112375_bib68 article-title: First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine publication-title: Oncology doi: 10.1159/000227243 – volume: 34 start-page: 4203 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib99 article-title: Obesity and breast cancer prognosis: evidence, challenges, and opportunities publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.68.4480 – volume: 22 start-page: 7396 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib37 article-title: Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death publication-title: Oncogene doi: 10.1038/sj.onc.1206943 – volume: 13 start-page: 1083 issue: 11 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib151 article-title: Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70222-4 – ident: 10.1016/j.biopha.2021.112375_bib79 doi: 10.2147/CMAR.S178567 – volume: 128 start-page: 783 year: 2011 ident: 10.1016/j.biopha.2021.112375_bib103 article-title: Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-011-1612-1 – volume: 9 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib125 article-title: Penfluridol overcomes paclitaxel resistance in metastatic breast cancer publication-title: Sci. Rep. doi: 10.1038/s41598-019-41632-0 – volume: 14 start-page: 67 year: 2011 ident: 10.1016/j.biopha.2021.112375_bib39 article-title: Nanotherapeutics to overcome conventional cancer chemotherapy limitations publication-title: J. Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci. Soc. Can. Des. Sci. Pharm. – volume: 7 year: 2012 ident: 10.1016/j.biopha.2021.112375_bib55 article-title: Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer publication-title: PLoS One – volume: 11 start-page: 3295 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib114 article-title: The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S200059 – volume: 171 start-page: 1 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib22 article-title: Impact of cost on the safety of cancer pharmaceuticals publication-title: Cancer Treat. Res doi: 10.1007/978-3-319-43896-2_1 – volume: 15 start-page: 5445 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib94 article-title: Recent advances in designing 5-fluorouracil delivery systems: a stepping stone in the safe treatment of colorectal cancer publication-title: Int. J. Nanomed. doi: 10.2147/IJN.S257700 – volume: 11 start-page: 5135 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib119 article-title: Antibiotics for cancer treatment: a double-edged sword publication-title: J. Cancer doi: 10.7150/jca.47470 – volume: 7 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib102 article-title: Metformin as an adjuvant in breast cancer treatment publication-title: SAGE Open Med. doi: 10.1177/2050312119865114 – volume: 69 start-page: 313 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib9 article-title: Breast cancer in young women: an overview publication-title: Updates Surg. doi: 10.1007/s13304-017-0424-1 – volume: 26 start-page: 549 year: 2009 ident: 10.1016/j.biopha.2021.112375_bib105 article-title: Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis publication-title: Pharm. Res. doi: 10.1007/s11095-008-9770-5 – volume: 321 start-page: 288 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib11 article-title: Breast cancer treatment: a review publication-title: JAMA J. Am. Med. Assoc. doi: 10.1001/jama.2018.19323 – volume: 48 start-page: 774 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib71 article-title: Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation publication-title: Int. J. Oncol. doi: 10.3892/ijo.2015.3298 – volume: 5 start-page: 275 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib32 article-title: Tumour stem cells and drug resistance publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1590 – volume: 37 start-page: 403 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib43 article-title: Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment publication-title: Oncogene doi: 10.1038/onc.2017.328 – volume: 3 start-page: 23 year: 2009 ident: 10.1016/j.biopha.2021.112375_bib82 article-title: Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro publication-title: Breast Cancer – volume: 36 start-page: 885 year: 2002 ident: 10.1016/j.biopha.2021.112375_bib77 article-title: Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells publication-title: Hepatology – volume: 117 start-page: 1422 year: 2007 ident: 10.1016/j.biopha.2021.112375_bib104 article-title: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action publication-title: J. Clin. Investig. doi: 10.1172/JCI30558 – start-page: 1 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib147 article-title: Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the publication-title: Off. J. Eur. Union – volume: 18 start-page: 41 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib18 article-title: Drug repurposing: progress, challenges and recommendations publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.168 – volume: 24 start-page: 3659 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib121 article-title: Penfluridol as a candidate of drug repurposing for anticancer agent publication-title: Molecules doi: 10.3390/molecules24203659 – volume: 7 start-page: 199 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib108 article-title: Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-13-0181 – volume: 3 year: 2008 ident: 10.1016/j.biopha.2021.112375_bib107 article-title: Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 publication-title: J. Mol. Signal. doi: 10.1186/1750-2187-3-18 – volume: 76 start-page: 877 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib122 article-title: Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in triple-negative breast cancer by inhibiting integrin signaling axis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-1233 – volume: 358 start-page: 1663 year: 2008 ident: 10.1016/j.biopha.2021.112375_bib67 article-title: Weekly paclitaxel in the adjuvant treatment of breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0707056 – volume: 20 start-page: 85 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib21 article-title: 2020 FDA drug approvals publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-021-00002-0 – volume: 95 start-page: 195 year: 2012 ident: 10.1016/j.biopha.2021.112375_bib15 article-title: The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells publication-title: Colloids Surf. B Biointerfaces doi: 10.1016/j.colsurfb.2012.02.039 – volume: 22 start-page: 1 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib112 article-title: Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2 publication-title: Oncol. Lett. doi: 10.3892/ol.2021.12876 – volume: 5 start-page: 1 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib149 article-title: Overcoming cancer therapeutic bottleneck by drug repurposing publication-title: Signal Transduct. Target. Ther. – volume: 68 start-page: 8 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib1 article-title: Drug repurposing for breast cancer therapy: old weapon for new battle publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.09.012 – volume: 0 start-page: 2996 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib13 article-title: Pathway-based drug-repurposing schemes in cancer: the role of translational bioinformatics publication-title: Front. Oncol. – volume: 12 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib153 article-title: Lack of effectiveness of repurposed drugs for COVID-19 treatment publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.635371 – volume: 151 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib26 article-title: Understanding Breast cancer: from conventional therapies to repurposed drugs publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2020.105401 – volume: 37 start-page: 435 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib3 article-title: Serendipity in cancer drug discovery: rational or coincidence? publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2016.03.004 – start-page: 1 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib138 article-title: Doxorubicin publication-title: XPharm Compr. Pharmacol. Ref. – volume: 178 start-page: 327 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib14 article-title: A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-019-05381-y – volume: 11 start-page: 2421 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib98 article-title: Metformin: a review of its potential indications publication-title: Drug Des. Dev. Ther. doi: 10.2147/DDDT.S141675 – volume: 102 start-page: 1855 year: 2010 ident: 10.1016/j.biopha.2021.112375_bib116 article-title: Effect of nitroxoline on angiogenesis and growth of human bladder cancer publication-title: JNCI J. Natl. Cancer Inst. doi: 10.1093/jnci/djq457 – volume: 0 start-page: 1664 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib146 article-title: On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients publication-title: Front. Pharmacol. doi: 10.3389/fphar.2019.01664 – volume: 14 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib80 article-title: Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice publication-title: PLoS One doi: 10.1371/journal.pone.0224309 – volume: 94 start-page: 1615 year: 2006 ident: 10.1016/j.biopha.2021.112375_bib143 article-title: The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6603158 – volume: 110 start-page: 507 year: 1993 ident: 10.1016/j.biopha.2021.112375_bib57 article-title: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.1993.tb13840.x – volume: 57 start-page: 727 year: 1999 ident: 10.1016/j.biopha.2021.112375_bib140 article-title: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin publication-title: Biochem. Pharmacol. doi: 10.1016/S0006-2952(98)00307-4 – volume: 13 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib96 article-title: Cellulose nanofiber-based hydrogels embedding 5-FU promote pyroptosis activation in breast cancer cells and support human adipose-derived stem cell proliferation, opening new perspectives for breast tissue engineering publication-title: Pharmaceutics doi: 10.3390/pharmaceutics13081189 – volume: 200 start-page: 138 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib41 article-title: Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications publication-title: J. Control. Release doi: 10.1016/j.jconrel.2014.12.030 – volume: 219 start-page: 202 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib142 article-title: Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer publication-title: J. Surg. Res. doi: 10.1016/j.jss.2017.05.101 – volume: 608 start-page: 1 year: 2007 ident: 10.1016/j.biopha.2021.112375_bib31 article-title: Overview of resistance to systemic therapy in patients with breast cancer publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-0-387-74039-3_1 – volume: 147 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib75 article-title: A journey of celecoxib from pain to cancer publication-title: Prostaglandins Other Lipid Mediat. doi: 10.1016/j.prostaglandins.2019.106379 – volume: 16 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib97 article-title: Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer publication-title: PLoS One doi: 10.1371/journal.pone.0252822 – volume: 10 start-page: 654 issue: 7 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib115 article-title: Recent advances in drug repositioning for the discovery of new anticancer drugs publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.9224 – volume: 10 start-page: 200 issue: 200 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib6 article-title: Drug repurposing for triple-negative breast cancer publication-title: J. Pers. Med. doi: 10.3390/jpm10040200 – volume: 9 start-page: 73 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib65 article-title: Everolimus in the treatment of metastatic breast cancer publication-title: Breast Cancer – volume: 10 start-page: 1 year: 2008 ident: 10.1016/j.biopha.2021.112375_bib74 article-title: Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model publication-title: Breast Cancer Res. doi: 10.1186/bcr1864 – volume: 13 start-page: 1393 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib84 article-title: Celecoxib up regulates the expression of drug efflux transporter ABCG2 in breast cancer cell lines publication-title: Iran. J. Pharm. Res. IJPR – volume: 534 start-page: 314 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib19 article-title: Can you teach old drugs new tricks? publication-title: Nature doi: 10.1038/534314a – volume: 12 start-page: 189 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib73 article-title: High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: case series and review of the literature publication-title: Hematol. Oncol. Stem Cell Ther. doi: 10.1016/j.hemonc.2019.08.008 – volume: 16 start-page: 205 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib124 article-title: Penfluridol represses integrin expression in breast cancer through induction of reactive oxygen species and downregulation of Sp transcription factors publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0451 – volume: 289 start-page: 27 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib93 article-title: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line publication-title: Exp. Cell Res. doi: 10.1016/S0014-4827(03)00223-4 – volume: 137 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib95 article-title: 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2021.111285 – volume: 282 start-page: 1921 year: 1999 ident: 10.1016/j.biopha.2021.112375_bib78 article-title: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.282.20.1921 – volume: 137 start-page: 9 year: 2011 ident: 10.1016/j.biopha.2021.112375_bib88 article-title: Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-010-0854-3 – volume: 62 start-page: 1 year: 2007 ident: 10.1016/j.biopha.2021.112375_bib7 article-title: What is cancer? publication-title: Adv. Nucl. Oncol. – volume: 312 start-page: 11 issue: 1 year: 2011 ident: 10.1016/j.biopha.2021.112375_bib117 article-title: Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline) publication-title: Cancer Lett. doi: 10.1016/j.canlet.2011.06.032 – volume: 30 start-page: 2844 year: 2012 ident: 10.1016/j.biopha.2021.112375_bib100 article-title: Diabetes, metformin, and breast cancer in postmenopausal women publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.39.7505 – volume: 9 start-page: 465 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib63 article-title: Fulvestrant in advanced breast cancer: evidence to date and place in therapy publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/1758834017711097 – volume: 180 start-page: 424 year: 2000 ident: 10.1016/j.biopha.2021.112375_bib52 article-title: Understanding patterns of failure in breast cancer treatment argues for a more thorough investigation of axillary lymph nodes in node negative patients publication-title: Am. J. Surg. doi: 10.1016/S0002-9610(00)00507-9 – volume: 355 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib135 article-title: Tamoxifen benefits women who have had invasive breast cancer, community study finds publication-title: BMJ – volume: 22 start-page: 1 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib72 article-title: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-a trial publication-title: Breast Cancer Res. doi: 10.1186/s13058-020-01348-w – volume: 24 year: 2010 ident: 10.1016/j.biopha.2021.112375_bib10 article-title: Overexpression of BDNF and TrkB in human bladder cancer specimens publication-title: Oncol. Rep. – volume: 17 start-page: 53 issue: 1 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib118 article-title: Nitroxoline induces apoptosis and slows glioma growth in vivo publication-title: Neuro Oncol. doi: 10.1093/neuonc/nou139 – volume: 9 start-page: 1077 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib61 article-title: Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective publication-title: Onco Targets Ther. – volume: 17 start-page: 285 year: 1999 ident: 10.1016/j.biopha.2021.112375_bib130 article-title: Antiestrogens--tamoxifen, SERMs and beyond publication-title: Investig. New Drugs doi: 10.1023/A:1006348907994 – volume: 501 start-page: 346 year: 2013 ident: 10.1016/j.biopha.2021.112375_bib35 article-title: Influence of tumour micro-environment heterogeneity on therapeutic response publication-title: Nature doi: 10.1038/nature12626 – volume: 11 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib128 article-title: Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer publication-title: Front. Pharmacol. doi: 10.3389/fphar.2020.592912 – volume: 59 start-page: 1535 issue: 7 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib152 article-title: Topiramate use does not reduce flares of inflammatory bowel disease publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-014-3040-7 – volume: 2 start-page: 15 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib34 article-title: Role of solute carriers in response to anticancer drugs publication-title: Mol. Cell. Ther. doi: 10.1186/2052-8426-2-15 – volume: 20 start-page: 1236 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib101 article-title: Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis publication-title: Oncologist doi: 10.1634/theoncologist.2015-0096 – volume: 14 start-page: 1 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib58 article-title: Toremifene for breast cancer: a review of 20 years of data publication-title: Clin. Breast Cancer doi: 10.1016/j.clbc.2013.10.014 – volume: 8 start-page: 1 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib56 article-title: Palbociclib in metastatic breast cancer: current evidence and real-life data publication-title: Drugs Context doi: 10.7573/dic.212579 – volume: 568 start-page: 254 issue: 5687751 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib111 article-title: Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism publication-title: Nature doi: 10.1038/s41586-019-1005-x – year: 2020 ident: 10.1016/j.biopha.2021.112375_bib109 article-title: Metformin activity against breast cancer: mechanistic differences by molecular subtype and metabolic conditions publication-title: Metformin [Work. Title] – volume: 2020 51 start-page: 1 issue: 5 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib113 article-title: Overcoming cancer therapeutic bottleneck by drug repurposing publication-title: Signal Transduct. Target. Ther. – volume: 10 start-page: 4653 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib81 article-title: Celecoxib in breast cancer prevention and therapy publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S178567 – volume: 14 start-page: 1 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib4 article-title: Repurposing of approved cardiovascular drugs publication-title: J. Transl. Med. doi: 10.1186/s12967-016-1031-5 – volume: 9 start-page: 1 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib123 article-title: Penfluridol overcomes paclitaxel resistance in metastatic breast cancer publication-title: Sci. Rep. doi: 10.1038/s41598-019-41632-0 – volume: 164 start-page: 326 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib16 article-title: Salinomycin inhibits breast cancer progression via targeting HIF-1α/VEGF mediated tumor angiogenesis in vitro and in vivo publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2019.04.026 – volume: 24 start-page: 111 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib110 article-title: Metformin and breast cancer: molecular targets publication-title: J. Mammary Gland Biol. Neoplasia. doi: 10.1007/s10911-019-09429-z – ident: 10.1016/j.biopha.2021.112375_bib25 – volume: 7 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib2 article-title: Drug combination and repurposing for cancer therapy: the example of breast cancer publication-title: Heliyon doi: 10.1016/j.heliyon.2021.e05948 – volume: 7 start-page: 4339 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib42 article-title: Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: a prospective study publication-title: Cancer Med. doi: 10.1002/cam4.1687 – volume: 0 start-page: 2148 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib126 article-title: Psychotropic drugs show anticancer activity by disrupting mitochondrial and lysosomal function publication-title: Front. Oncol. – volume: 1 start-page: 334 year: 2001 ident: 10.1016/j.biopha.2021.112375_bib59 article-title: Raloxifene for the treatment and prevention of breast cancer? publication-title: Expert Rev. Anticancer Ther. doi: 10.1586/14737140.1.3.334 – volume: 97 start-page: 1652 issue: 22 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib134 article-title: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/dji372 – volume: 137 start-page: 321 year: 2011 ident: 10.1016/j.biopha.2021.112375_bib86 article-title: Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-010-0893-9 – volume: 7 start-page: 8 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib36 article-title: Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases publication-title: Oncogenesis doi: 10.1038/s41389-017-0025-3 – volume: 2 start-page: 221 year: 1997 ident: 10.1016/j.biopha.2021.112375_bib92 article-title: 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene publication-title: Apoptosis doi: 10.1023/A:1026476801463 – volume: 65 start-page: 2513 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib66 article-title: Docetaxel: a review of its use in metastatic breast cancer publication-title: Drugs doi: 10.2165/00003495-200565170-00007 – volume: 64 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib154 article-title: Clinical trials of repurposed antivirals for SARS-CoV-2 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01101-20 – volume: 439 start-page: 58 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib40 article-title: Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques publication-title: Thermochim. Acta doi: 10.1016/j.tca.2005.09.011 – ident: 10.1016/j.biopha.2021.112375_bib20 doi: 10.1007/978-3-662-11496-4_24 – volume: 83 start-page: 4514 year: 1986 ident: 10.1016/j.biopha.2021.112375_bib141 article-title: Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.83.12.4514 – volume: 1152 start-page: 413 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib27 article-title: Current and emerging 3D models to study breast cancer publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-030-20301-6_22 – volume: 10 start-page: 418 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib69 article-title: Addition of capecitabine in breast cancer first-line chemotherapy improves survival of breast cancer patients publication-title: J. Cancer doi: 10.7150/jca.29739 – volume: 77 start-page: 365 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib53 article-title: Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-015-2947-9 – volume: 364 start-page: 2381 year: 2011 ident: 10.1016/j.biopha.2021.112375_bib60 article-title: Exemestane for breast-cancer prevention in postmenopausal women publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1103507 – volume: 333 start-page: 754 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib139 article-title: Characterization of the organic cation transporter SLC22A16: a doxorubicin importer publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2005.05.174 – year: 2020 ident: 10.1016/j.biopha.2021.112375_bib50 article-title: Types of breast cancer: triple negative, ER-Positive, HER2-Positive publication-title: WebMD Med. Ref. – volume: 3 start-page: 330 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib70 article-title: 5-fluorouracil: mechanisms of action and clinical strategies publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1074 – volume: 2 start-page: 141 year: 2019 ident: 10.1016/j.biopha.2021.112375_bib30 article-title: Drug resistance and combating drug resistance in cancer publication-title: Cancer Drug Resist. – volume: 3 start-page: 228 year: 2004 ident: 10.1016/j.biopha.2021.112375_bib83 article-title: Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro publication-title: Cancer Biol. Ther. doi: 10.4161/cbt.3.2.692 – volume: 38 start-page: 756 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib76 article-title: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis publication-title: Hepatology doi: 10.1053/jhep.2003.50380 – volume: 26 start-page: 1533 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib51 article-title: Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdv221 – volume: 83 start-page: 861 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib91 article-title: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma publication-title: Lab. Investig. doi: 10.1097/01.LAB.0000073128.16098.31 – volume: 19 start-page: 683 year: 2003 ident: 10.1016/j.biopha.2021.112375_bib62 article-title: Focus on anastrozole and breast cancer publication-title: Curr. Med. Res. Opin. doi: 10.1185/030079903125002397 – ident: 10.1016/j.biopha.2021.112375_bib137 doi: 10.1200/JCO.20.02598 – ident: 10.1016/j.biopha.2021.112375_bib23 – volume: 68 start-page: 209 year: 2021 ident: 10.1016/j.biopha.2021.112375_bib45 article-title: Turning liabilities into opportunities: off-target based drug repurposing in cancer publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2020.02.003 – volume: 25 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib106 article-title: Metformin causes cancer cell death through downregulation of p53-dependent differentiated embryo chondrocyte 1 publication-title: J. Biomed. Sci. doi: 10.1186/s12929-018-0478-5 – volume: 60 start-page: 153 year: 2000 ident: 10.1016/j.biopha.2021.112375_bib17 article-title: Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells publication-title: Breast Cancer Res. Treat. doi: 10.1023/A:1006338232150 – volume: 31 start-page: 58 year: 2012 ident: 10.1016/j.biopha.2021.112375_bib33 article-title: Multidrug resistance associated proteins in multindrung resistance publication-title: Chin. J. Cancer doi: 10.5732/cjc.011.10329 – volume: 27 start-page: 4522 year: 2009 ident: 10.1016/j.biopha.2021.112375_bib144 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.20.5013 – volume: 36 start-page: 1691 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib54 article-title: Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series publication-title: Neurol. Sci. doi: 10.1007/s10072-015-2259-1 – volume: 1 start-page: 35 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib8 article-title: Breast cancer therapy: a mini review publication-title: MOJ Drug Des. Dev. Ther. – volume: 10 year: 2018 ident: 10.1016/j.biopha.2021.112375_bib28 article-title: Aptamer therapeutics in cancer: current and future publication-title: Cancers doi: 10.3390/cancers10030080 – volume: 12 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib47 article-title: Development of strategies for the use of anti-growth factor treatments publication-title: Endocr. Relat. Cancer doi: 10.1677/erc.1.01004 – volume: 9 start-page: 321 year: 2008 ident: 10.1016/j.biopha.2021.112375_bib48 article-title: Genetic predisposition to breast cancer: past, present, and future publication-title: Annu. Rev. Genom. Hum. Genet. doi: 10.1146/annurev.genom.9.081307.164339 – volume: 34 start-page: 508 year: 2013 ident: 10.1016/j.biopha.2021.112375_bib12 article-title: Cancer drug discovery by repurposing: teaching new tricks to old dogs publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2013.06.005 – volume: 108 start-page: 181 year: 2009 ident: 10.1016/j.biopha.2021.112375_bib87 article-title: Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner publication-title: J. Cell. Biochem. doi: 10.1002/jcb.22239 – volume: 32 start-page: 1 year: 2020 ident: 10.1016/j.biopha.2021.112375_bib145 article-title: Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center publication-title: J. Egypt. Natl. Cancer Inst. – volume: 85 start-page: 1 issue: Suppl 2 year: 2001 ident: 10.1016/j.biopha.2021.112375_bib64 article-title: Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women publication-title: Br. J. Cancer – volume: 6 year: 2016 ident: 10.1016/j.biopha.2021.112375_bib132 article-title: Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance publication-title: Sci. Rep. doi: 10.1038/srep21164 – volume: 10 start-page: 647 year: 2004 ident: 10.1016/j.biopha.2021.112375_bib85 article-title: Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype publication-title: Curr. Pharm. Des. doi: 10.2174/1381612043453117 – ident: 10.1016/j.biopha.2021.112375_bib49 doi: 10.1007/978-1-4419-0802-5_18 – volume: 8 year: 2014 ident: 10.1016/j.biopha.2021.112375_bib148 article-title: The repurposing drugs in oncology (ReDO) project publication-title: Ecancermedicalscience doi: 10.3332/ecancer.2014.485 – volume: 6 start-page: 19027 year: 2015 ident: 10.1016/j.biopha.2021.112375_bib120 article-title: Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity publication-title: Oncotarget doi: 10.18632/oncotarget.3699 – volume: 456 start-page: 663 issue: 7222 year: 2008 ident: 10.1016/j.biopha.2021.112375_bib129 article-title: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen publication-title: Nature doi: 10.1038/nature07483 – volume: 93 start-page: 335 year: 2013 ident: 10.1016/j.biopha.2021.112375_bib46 article-title: Computational drug repositioning: from data to therapeutics publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2013.1 – volume: 8 start-page: 573 year: 2017 ident: 10.1016/j.biopha.2021.112375_bib44 article-title: A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information publication-title: Nat. Commun. doi: 10.1038/s41467-017-00680-8 – volume: 27 start-page: 602 year: 2005 ident: 10.1016/j.biopha.2021.112375_bib89 article-title: Rho GTPase expression in tumourigenesis: evidence for a significant link publication-title: Bioessays doi: 10.1002/bies.20238 – volume: 8 year: 2010 ident: 10.1016/j.biopha.2021.112375_bib90 article-title: Rac and Rho GTPases in cancer cell motility control publication-title: Cell Commun. Signal. doi: 10.1186/1478-811X-8-23 |
| SSID | ssj0005638 |
| Score | 2.5551414 |
| SecondaryResourceType | review_article |
| Snippet | Breast cancer (BC) is mostly observed in women and is responsible for huge mortality in women subjects globally. Due to the continued development of drug... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 112375 |
| SubjectTerms | Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Drug Repositioning Drug repurposing Drug resistance Drug Resistance, Neoplasm Female Genomics - methods Humans Molecular mechanism Proteomics - methods Repurposing challenges |
| Title | Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges |
| URI | https://dx.doi.org/10.1016/j.biopha.2021.112375 https://www.ncbi.nlm.nih.gov/pubmed/34863612 https://www.proquest.com/docview/2607303154 |
| Volume | 145 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEB9EQfpSrB_t1SpTKD6Z3sbdJHe-HbZyVSqCCr4t-5VypSTHJffgS__2zuTjtGAR-hpmSZiZnflt9jczAJ_GzsaeNlmUk3NEyss8ssIkkQgxT3oInDaZbXGVTu_UxX1yvwZnfS0M0yq72N_G9CZad0-GnTaH89lseEPJTkq-KIgZ1oy54FepjL388-8nNI-0mWbNwhFL9-VzDcfLzkpuynRCiY5raSSzDZ9PT_-Cn00aOt-C1x1-xEn7iW9gLRTbsPm9uyHfhqPrthf1wzHePpZWVcd4hNePXaofdsB9WSx_VLgIc1J1WQV_ipMCe0oAkvHnWDec2goJJOKKkY5ljpap7DU6ll2gKTyazsy01PXzWapduDv_ens2jbqJC5FTmarpVCpM7oW0IvfBSW-CzdPY56TGoITztEeDNzIYrodNnItDmjHxeiRj56yJ5R6sF2UR3gG6MZ2sRvk4I0ynRLDGBWGd8IaCROITMwDZK1q7rh05T8X4pXve2U_dmkezeXRrngFEq1Xzth3HC_JZb0P9l1tpyhgvrPzYm1zTjuNrFFOEcllpOgFSWJSEPQfwtvWF1bdINUolgcb3__3efXh1whUWzV-eD7BeL5bhgHBPbQ8bxz6Ejcm3y-nVH96eAvA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9tADBddCttextZ9ZVs3DUafanLu2U6yt9CupGsbCkuhb8d9uWQMO8TOQ__7SfY5YdBR6Ks5YSPppN_5fpIAvo2tiR1tsign54gSJ_PICJ1Gwsc86cFz2mS2xSybXic_b9KbHTjuamGYVhlifxvTm2gdngyCNgfLxWLwi5KdlHxREDOsGY-ewC53p0p7sDs5O5_OtkyPrBlozesjFugq6Bqal1mU3JfpiHIdl9NIJhzen6H-h0CbTHT6El4ECImT9itfwY4v9uDpZbgk34ODq7Yd9d0hzrfVVdUhHuDVtlH13WuwJ6v1bYUrvyRtl5V333FSYMcKQLL_EuuGVlsh4UTckNKxzNEwm71Gy2tXqAuHOliaRG03oqV6A9enP-bH0ygMXYhsMkxqOpgKnTshjcidt9Jpb_Isdjmp0SfCOtqm3mnpNZfEptbGPhsy93okY2uNjuVb6BVl4d8D2jEdrkb5eEiwLhHeaOuFscJpihOpS3UfZKdoZUNHch6M8Ud11LPfqjWPYvOo1jx9iDZSy7YjxwPrh50N1T-epShpPCD5tTO5ok3HNym68OW6UnQIpMgoCX724V3rC5tvkckok4QbPzz6vV_g2XR-eaEuzmbnH-H5ERdcND99PkGvXq39PsGg2nwObv4XtGoFoQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Drugs+repurposed%3A+An+advanced+step+towards+the+treatment+of+breast+cancer+and+associated+challenges&rft.jtitle=Biomedicine+%26+pharmacotherapy&rft.au=Malik%2C+Jonaid+Ahmad&rft.au=Ahmed%2C+Sakeel&rft.au=Jan%2C+Bisma&rft.au=Bender%2C+Onur&rft.date=2022-01-01&rft.issn=1950-6007&rft.eissn=1950-6007&rft.volume=145&rft.spage=112375&rft_id=info:doi/10.1016%2Fj.biopha.2021.112375&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0753-3322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0753-3322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0753-3322&client=summon |